Helping you make better health choices

In shops now or delivered to your home from only £3.50 an issue!



MagazineMay 2005 (Vol. 16 Issue 2)Adderall,

FDA sits and waits amid Adderall deaths

FDA sits and waits amid Adderall deaths. Many are aware of the dangerous side-effects of amphetamines, especially when they are used to treat children with attention-deficit/hyperactivity disorder (ADHD). Yet, it has taken 20 sudden deaths and 12 fatal strokes to jolt Health Canada, the Canadian health-regulatory body, into action, suspending sales of Adderall, the extended-release antihyperactivity drug linked to the fatalities. The worldwide death count is 16 children (14 sudden deaths, 2 strokes) between 1999 and 2003.

That US regulatory body is taking a 'wait-and-see' approach in response to the reports, arguing that as the rate of sudden death in pediatric patients treated with Adderall is based on approximately 30 million prescriptions . . . it does not appear that the number of deaths reported is greater than the number of sudden deaths that would be expected to occur in this population without treatment.

In other words, the FDA is telling parents who may have lost their children to Adderall that there aren't enough deaths yet for the agency to take it seriously (; 10 February 2005).

Vitamin E is my elixir of youth

Clever invention

You may also be interested in...

Sign up for free today

Sign up now to get your FREE 17-point Plan to Great Health

Free membership gives you access to our latest news reports, use of our community area, forums, blogs, readers' health tips and our twice-weekly
e-news letter.

WDDTY Recommends

Latest Tweet


Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, cancer, depression and many other chronic conditions.

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

Most Popular Health Website of the Year 2014

© 2010 - 2016 WDDTY Publishing Ltd.
All Rights Reserved